UTUC Is it Biologically Distinct
Donna E. Hansel, MD, PhD delves into the molecular and genetic differences that define Upper tract urothelial carcinoma (UTUC).
Read More
2022
Appropriate Use of PSMA PET in Clinical Practice
In this 10-minute video, Thomas Hope, MD, Assistant Professor in Abdominal Imaging and Nuclear Medicine in the Department of Radiology at the University of California, San Francisco, discusses the appropriate use criteria (AUC) of PSMA PET in clinical practice. He summarizes the guidelines for the appropriate use of PSMA PET and delves into the studies that inform them.
Read More
Posterior Urethral Stenosis (PUS) After Prostate Cancer Therapy
In this 21-minute video, Brian J. Flynn, MD, Co-Director of Female Pelvic Medicine and Reconstructive Surgery, Reconstructive Urology, and associate professor at the University of Colorado, discusses Posterior Urethral Stenosis (PUS) after prostate cancer therapy and the existing and developing techniques used to address it. He then examines the various treatments used for PUS, such as dilation or transurethral incision (TUI), and considers the advantages and disadvantages of each technique.
Read More
Enhancing Your Productivity Using Disposable Cystoscopes
In this 7-minute video, Grand Rounds in Urology Contributing Editor Neil H. Baum, MD, Professor of Urology at Tulane Medical School, discusses the use of disposable cystoscopes to improve physician productivity and efficiency without additional overhead or compromising patient care.
Read More
Advanced Prostate Cancer Clinical Trials Updates
David S. Morris, MD, FACS, of Urology Associates, PC in Nashville, Tennessee discusses advanced prostate cancer updates, including those shared recently at medical conferences including the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU) as well as several studies, namely the STAMPEDE trial, PEACE-1, ARASENS, ENZAMET, PROpel, and MAGNITUDE. Dr. Morris unpacks the takeaways, explaining that doctors should consider adding abiraterone to androgen deprivation therapy (ADT) for high-risk, non-metastatic disease; consider adding abiraterone or darolutamide for patients with mCSPC whose therapy will include using docetaxel; and consider adding poly-ADP-ribose polymerase inhibitors (PARPi) to abiraterone in patients with first-line mCRPC.
Read More